Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001873515-25-000004·5AM Opportunities II (GP), LLC
Schedule 13G ownership disclosure
Zentalis Pharmaceuticals, Inc.
Common Stock, $0.001 par value per share · CUSIP: 98943L107
Event date: 2025-12-18
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- 5AM Opportunities II (GP), LLC
Shares: 3,947,913.00 · Class: 5.2%
- 5AM Opportunities II, L.P.
Shares: 3,947,913.00 · Class: 5.2%
- 5AM Opportunities (GP), LLC
Shares: 890,658.00 · Class: 1.2%
- 5AM Opportunities Master Fund L.P.
Shares: 890,658.00 · Class: 1.2%
- Andrew J. Schwab
Shares: 4,838,571.00 · Class: 6.4%
- Kush Parmar
Shares: 4,838,571.00 · Class: 6.4%
- Anna Yaeger
Shares: 890,658.00 · Class: 1.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001873515-25-000004
- Form type
- SCHEDULE 13G
- Filer
- 5AM Opportunities II (GP), LLC
- CIK
- CIK 1873515
- Filed
- Dec 30, 2025
- Reporting period
- Dec 18, 2025
- Description
- Schedule 13G beneficial ownership